Interferon-γ-induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis

被引:22
作者
Berthou, C
Bourge, JF
Zhang, YH
Soulié, A
Geromin, D
Denizot, Y
Sigaux, F
Sasportes, M
机构
[1] Hop St Louis, INSERM, U462, F-75475 Paris 10, France
[2] Fac Med, CNRS, EP 118, Limoges, France
关键词
D O I
10.1182/blood.V95.7.2329.007k34_2329_2336
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Perforin is known to display a membranolytic activity on tumor cells, Nevertheless, perforin release during natural killer (NK)cell activation is not sufficient to induce membrane target-cell damage. On the basis of the ability of perforin to interact with phospholipids containing a choline phosphate headgroup, we identify the platelet-activating factor (PAF) and its membrane receptor as crucial components in tumor cell killing activity of human resting NK cells. We demonstrate for the first time that upon activation, naive NK cells release the choline phosphate-containing lysolipid PAF, which binds to perforin and acts as an agonist on perforin-induced membrane damage. PAF is known to incorporate cell membranes using a specific receptor. Here we show that interferon-gamma (IFN-gamma) secreted from activated NK cells ends in PAF-receptor expression on perforin-sensitive K562 cells but not on perforin-resistant Daudi cells. In order to prove the capacity of PAF to interact simultaneously with its membrane PAF receptor and with perforin, we successfully co-purified the 3 components in the presence of bridging PAF molecules. The functional activity of this complex was further examined. The aim was to determine whether membrane PAF-receptor expression on tumor cells, driven to express this receptor, could render them sensitive to the perforin lytic pathway. The results confirmed that transfection of the PAF-receptor complementary DNA into major histocompatibility complex class I and Fas-receptor negative tumor cells restored susceptibility to naive NK cells and perforin attack. Failure of IFN-gamma to induce membrane PAF receptor constitutes the first described mechanism for tumor cells to resist the perforin lytic pathway. (Blood. 2000;95:2329-2336) (C) 2000 by The American Society of Hematology.
引用
收藏
页码:2329 / 2336
页数:8
相关论文
共 52 条
[1]   BINDING OF PERFORIN TO MEMBRANES IS SENSITIVE TO LIPID SPACING AND NOT HEADGROUP [J].
ANTIA, R ;
SCHLEGEL, RA ;
WILLIAMSON, P .
IMMUNOLOGY LETTERS, 1992, 32 (02) :153-158
[2]   Interferon gamma production by natural killer (NK) cells and NK1.1(+) T cells upon NKR-P1 cross-linking [J].
Arase, H ;
Arase, N ;
Saito, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (05) :2391-2396
[3]  
Berthou C, 1997, J IMMUNOL, V159, P5293
[4]   CORD-BLOOD T-LYMPHOCYTES LACK CONSTITUTIVE PERFORIN EXPRESSION IN CONTRAST TO ADULT PERIPHERAL-BLOOD T-LYMPHOCYTES [J].
BERTHOU, C ;
LEGROSMAIDA, S ;
SOULIE, A ;
WARGNIER, A ;
GUILLET, J ;
RABIAN, C ;
GLUCKMAN, E ;
SASPORTES, M .
BLOOD, 1995, 85 (06) :1540-1546
[5]   Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells [J].
Bradley, M ;
Zeytun, A ;
Rafi-Janajreh, A ;
Nagarkatti, PS ;
Nagarkatti, M .
BLOOD, 1998, 92 (11) :4248-4255
[6]   DISSOCIATION OF NATURAL-KILLER AND LYMPHOCYTE-ACTIVATED KILLER-CELL LYTIC ACTIVITIES IN HUMAN CD3- LARGE GRANULAR LYMPHOCYTES [J].
CLEMENT, MV ;
LEGROSMAIDA, S ;
SOULIE, A ;
GUILLET, J ;
SASPORTES, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (03) :697-701
[7]   PAF AND HEMATOPOIESIS .3. PRESENCE AND METABOLISM OF PLATELET-ACTIVATING-FACTOR IN HUMAN BONE-MARROW [J].
DENIZOT, Y ;
TRIMOREAU, F ;
DUPUIS, F ;
VERGER, C ;
PRALORAN, V .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1995, 1265 (01) :55-60
[8]   Production, metabolism and effect of platelet-activating factor on the growth of the human K562 erythroid cell line [J].
Dupuis, F ;
Levasseur, S ;
Jean-Louis, F ;
Dulery, C ;
Praloran, V ;
Denizot, Y ;
Michel, L .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1997, 1359 (03) :241-249
[9]   METABOLISM OF PLATELET-ACTIVATING-FACTOR IN HUMAN HEMATOPOIETIC-CELL LINES - DIFFERENCES BETWEEN MYELOID AND LYMPHOID-CELLS [J].
GARCIA, MD ;
GARCIA, C ;
GIJON, MA ;
FERNANDEZGALLARDO, S ;
MOLLINEDO, F ;
CRESPO, MS .
BIOCHEMICAL JOURNAL, 1991, 273 :573-578
[10]  
GHADIALLY FN, 1988, ULTRASTRUCT PATHOL, V2, P1043